Craig Murphy, Ph.D., is co-founder and Chief Scientific Officer of Khartis Therapeutics. He is an accomplished immunologist and leader with more than 20 years of experience in the biopharmaceutical industry discovering small molecule, biologic, and peptide therapeutics. Craig was previously VP, Immunology at XinThera until the company’s sale to Gilead in 2023. Prior to that, Craig was leader of the GI and IL-23 Immunology Translational Science teams at Janssen R&D supporting programs and strategy across the Immunology portfolio. Craig’s career has been underlined by succession to positions of increasing responsibility at Schering-Plough Biopharma, Amgen, Protagonist Therapeutics, Ferring Pharmaceuticals, and Takeda. While at Protagonist, Craig served as Head of Discovery Research advancing 3 key assets that progressed to late-stage development, including the recently approved IL-23R oral antagonist, Icotyde.  At Ferring, as Senior Director of Immunology and GI Research Craig drove the overall GI research strategy and at Takeda led the GI Immunology Research team.